GlassScriptPhysician profile
Alan Fozailoff
NPI 1053331595
$746.47
in general payments reported to CMS, 2019-2025
12 companies · $90.28 in 2025
The $90.28 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.07 · 2020: $73.25 · 2021: $158 · 2022: $111 · 2023: $78.05 · 2024: $156 · 2025: $90.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $311 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $311.08 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $135.47 | 2019-2021 | |
| Amgen INC. | $118.47 | 2019-2025 | Evenity, Krystexxa, Prolia |
| Exact Sciences Corporation | $111.60 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $79.86 | 2022 | |
| Novartis Pharmaceuticals Corporation | $74.37 | 2021-2023 | |
| Pfizer INC. | $68.40 | 2020-2021 | |
| Glaxosmithkline, LLC. | $63.62 | 2022-2024 | Benlysta |
| Abbott Laboratories | $24.88 | 2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.04 | 2024 | Tradjenta, Jardiance |
| Merck Sharp & Dohme LLC | $17.08 | 2020 | |
| Amarin Pharma, INC. | $17.08 | 2021 | |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Fozailoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.